Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review

Biomarker Insights

Volumn 3, Issue , 2008, Pages

  Barnes, Dawn M ^a   Wakefield, Thomas W ^a   Rectenwald, John E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

D dimer; deep venous thrombosis; microparticles; P selectin

Indexed keywords

EID: 85128447330     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.1177/117727190800300004     Document Type: Review

References (71)

1. van Mourik J.A., Romani de Wit T., and Voorberg J. 2002. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem. Cell. Biol. 117: 113–22.
2. Myers D., Farris D., Hawley A. et al. 2002. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J. Surg. Res, 108: 212–21.
3. Frenette P.S., Moyna C. Hartwell D.W. et al. 1998. Platelet-endothelial interactions in inflamed mesenteric venules. Blood, 91: 1318–24.
4. Rectenwald J.E., Myers D.D., Hawley A.E. et al. 2005. D-Dimer, P-Selectin, and microparticles: novel markers to predict deep venous thrombosis. Thromb Haemost, 94: 1312–17.
5. Dunlop L.C., Skinner M.P., Bendall L.J. et al. 1992. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J. Exp. Med. 175: 1147–50.
6. Johnston G.I., Bliss G.A., Newman P.J. et al. 1990. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J. Biol. Chem., 265: 21381–85.
7. André P., Hartwell D., Hrachiovinová I. et al. 2000. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci U.S.A., 97(25): 13835–40.
8. Fijnheer R., Frijns C.J., Korteweg J. et al. 1997. The origin of P-selectin as a circulating plasma protein. Thromb Haemost, 77: 1081–85.
9. Berger G., Hartwell D.W., Wagner D.D. 1998. P-Selectin and platelet clearance. Blood, 92: 4446–52.
10. Michelson A.D., Barnard M.R., Hechtman H.B. et al. 1996. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc. Natl. Acad. Sci. U.S.A., 93: 11877–82.
11. Chong B.H., Murray B., Berndt M.C. et al. 1994. Plasma P-selec-tin is increased in thrombotic consumptive platelet disorders. Blood, 83: 1535–41.
12. Wu G., Li F., Li P. et al. 1993. Detection of plasma alpha-granule membrane protein GMP-140 using radiolabeled monoclonal antibodies in thrombotic diseases. Haemostasis, 23: 121–28.
13. Blann A.D., Dobrotova M., Kubisz P. et al. 1995. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost, 74: 626–30.
14. Smith A., Quarmby J.W., Collins M. et al. 1999. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Hoemost, 82: 1593–99.
15. Frijns C.J., Kappelle L.J., van, Gijn J. et al. 1997. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke, 11: 2214–18.
16. Verhaar M.C., Beutler J.J., Gaillard et al. 1998. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J. Hypertens, 16: 45–50.
17. Wagner D.D., Burger P.C. 2003. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol., 23: 2131–37.
18. Ridker P.M., Buring J.E., and Rifai N. 2001. Soluble P-selectin and the risk of future cardiovascular events. Circulation,103: 491–95.
19. Mayadas T.N., Johnson R.C., Rayburn H. et al. 1993. Leukocyte rolling and extravasation are severely compromised in P-selectin-deficient mice. Cell, 74: 541–54.
20. Palabrica T., Lobb R., Furie B.C. et al. 1992. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature, 359: 848–51.
21. Subramaniam M., Frenette P.S., Saffaripour S. et al. 1996. Defects in hemostasis in P-selectin-deficient mice. Blood, 87: 1238–42.
22. Gamble J.R., Skinner M.P., Berndt M.C., and Vadas M.A. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP140. Science 1190; 249: 414–17.
23. Wong C.S., Gamble J.R., Skinner M.P. et al. 1991. Adhesion protein GMP140 inhibits superoxide anion release by human neutrophils. Proc. Natl. Acad. Sci. U.S.A., 88: 2397–2401.
24. Evangelista V., Manarini S., Sideri R. et al. 1999. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood, 93: 876–85.
25. Von Andrian U.H., Hansell P., Chambers J.D. et al. 1992. L-selectin function is required for beta 2-integrin-mediated neutrophil adhesion at physiological shear rates in vivo. Am. J. Physiol. 263 (4 Pt 2): H1034–44.
26. Gilbert G.E., Sims P.J., Eidmer T. et al. 1991. Platelet-derived microparticles express high affinity receptors for factor VIII. J. Biol. Chem., 266: 17261–68.
27. Mesri M., Altieri D.C. 1998. Endothelial cell activation by leukocyte Microparticles. J. Immunol., 161: 4382–87.
28. Sabatier F., Roux V., Anfosso F. et al. 2002. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood, 99: 3962–70.
29. Falati S., Liu Q., Gross P. et al. 2003. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197: 1585–98.
30. Martinez M.C., Tesse A., Zobairi F. et al. 2005. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am. J. Physiol. Heart. Circ. Physiol., 288: H1004–9.
31. Furie B., Furie B.C. 2004. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends. Mol. Med, 10: 645–51.
32. Satta N., Toti F., Feugeas O. et al. 1994. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J. Immunol., 153: 3245–55.
33. Wakefield T.W., Strieter R.M., Downing L.J. et al. 1996. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J. Surg. Res. 64: 26–31.
34. Hrachovinova I., Cambien B., Hafezi-Moghadam A. et al. 2003. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med, 9: 1020–25.
35. Cambien B., Wagner D.D. 2004. A new role in hemostasis for the adhesion receptor P-selectin. TRENDS in Molec Med, 10(4): 179–86.
36. Frenette P.S., Denis C.V., Weiss L. et al. 2000. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J. Exp. Med. 191: 1413–22.
37. Blann A.D., Noteboom W.M., Rosendaal F.R. 2000. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br. J. Haematol., 108: 191–93.
38. Papalambrosm E., Sigala F., Travlou A. et al. 2004. P-selectin and antibodies against Heparin-Platelet factor 4 in patients with venous or arterial disease after a 7-day Heparin treatment. J. Am. Coll. Surg., 199: 69–77.
39. Stein P.D., Hull R.D., Patel K.C. et al. 2004. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann. Intern. Med., 140: 589–602.
40. Bounameaux H., Cirafici P., de Moerloose P. et al. 1991. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet, 337: 196–200.
41. Demers C., Ginsberg J.S., Johnston M. et al. 1992. D-dimer and thrombin-antithrombin III complexes in patients with clinically suspected pulmonary embolism. Thromb Haemost, 67: 408–12.
42. Khaira H.S., Mann J. 1998. Plasma D-dimer measurements in patients with suspected DVT–a means of avoiding unnecessary venography. Eur. J. Vasc. Endovasc. Surg, 15(3): 235–38.
43. Cosmi B., Legnani C., Cini M. et al. 2005. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep venous thrombosis. Thromb Haemost, 94: 969–74.
44. Linkins L.A., Choi P.O., and Douketis J.D. 2006. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann. Int. Med, 139: 893–900.
45. Palareti G., Cosmi B., Legnani C. et al. 2006. D-dimer testing to determine the duration of anticoagulation therapy. N. Engl. J. Med, 355(17): 1780–89.
46. Myers D.D., Hawley A.E., Farris D.M. et al. 2003. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J. Vasc. Surg. 38: 1075–89.
47. Jilma B., Kovar F., Hron G. et al. 2006. Homozygosity in the single nucleotide polymorphism Ser126Arg in the E-selectin gene associated with recurrent venous thromboembolism. Arch. Intern. Med, 166: 1655–59.
48. Ruvelle B.M., Scott D., and Beck P.J. 1996. Single amino acid residues in the E- and P-selectin epidermal growth factor domains can determine carbohydrate binding specificity. J. Biol. Chem, 271: 16160–170.
49. Rao R.M., Clarke J.L., Ortlepp S. et al. 2002. The S128R polymorphism of E-selectin mediates neuraminidase-resistant tethering of myeloid cells under shear flow. Eur. J. Immnol., 32: 251–60.
50. Yoshida M., Takano Y., Sasaoka T. et al. 2003. E-selectin polymorphism associated with myocardial infarction causes enhanced leukocyte-endothelial interactions under flow conditions. Arterioscler Thromb Vasc Biol., 23: 783–88.
51. Wenzel K., Blackburn Q., Ernst M. et al. 1997. Relationship of polymorphisms in the rennin-angiotensin system and in E-selectin of patients with early severe coronary heart disease. J. Mol. Med, 75: 57–61.
52. Ghilardi G., Biondi M.L., Turri O. et al. 2004. Ser128Arg gene polymorphism for E-selectin and severity of atherosclerotic arterial disease. J. Cardiovasc. Surg. (Torino) 45: 143–47.
53. Ellsworth D.L., Bielak L.F., Turner S.T. et al. 2001. Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification. J. Mol. Med, 79: 390–98.
54. Mlekusch W., Exner M., Schillinger M. et al. 2004. E-selectin and restenosis after femoropopliteal angioplasty: Prognostic impact of the Ser128Arg genotype and plasma levels. Thromb Haemost, 91: 171–79.
55. Jilma B., Marsik C., Kovar F. et al. 2005. The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia. Blood, 105: 238–83.
56. Hron G., Kollars M., Binder B. et al. 2006. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA, 296: 397–402.
57. Prandoni P., Lensing A.W., Cogo A. et al. 1996. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med, 125: 1–7.
58. Douketis J.D., Kearon C., Bates S. et al. 1998. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 279: 458–452.
59. Cochery-Nouvellon E., Vitry F., Cornillet-Lefebvre P. et al. 2006. Interleukin-10 promoter polymorphism and venous thrombosis–a case control study. Thromb Haemost, 96: 24–28.
60. Fiorentino D.F., Zlotnik A., Mossmann T.R. et al. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol., 147: 3815–22.
61. De Wall Malefyt R., Abrams J. et al. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med, 174: 1209–20.
62. Eskdale J., Gallagher G. 1995. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics, 42: 444–45.
63. Eskdale J., Kube D., and Gallagher G. 1996. A second polymorphic dinucleotide repeat in the 5′ flanking region of the human IL10 gene. Immunogenetics, 45: 82–83.
64. Downing L.J., Strieter R.M., Kadell A. et al. 1998. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J. Immunol, 161: 1471–76.
65. van der Zee P.M., Biro E., Ko Y. et al. 2006. P-selectin and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin. Chem, 52(4): 657–64.
66. Procoagulant microparticles: 2006. Disrupting the vascular homeostasis equation? Arterioscler. Thromb. Vasc. Biol., 26(12): 2594–604.
67. Bernal-Mizrachi L., Jy W., Fierro C. et al. 2004. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int. J. Cardiol, 97(3): 439–46.
68. Simak J., Gelderman M.P., Yu H. et al. 2006. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J. Thromb. Haemost, 4(6): 1296–302.
69. Chirinos J.A., Heresi G.A., Velasquez H. et al. 2005. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J. Am. Coll. Cardiol., 45(9): 1467–71.
70. Vogel G., Spanuth E. 1990. Predictive value of fibrin monomers in postoperative deep vein thrombosis. Klin Wochenschr, 68(20): 1020–6.
71. Schutgens R.E., Haas F.J., Agterof M.J. et al. 2007. The role of fibrin monomers in optimizing the diagnostic work-up of deep vein thrombosis. Thromb Haemost, 97(5): 807–13.